Siamab develops therapies targeting cancers that express abnormal carbohydrates (glycans) including ovarian, pancreatic, prostate, colon, breast and other solid tumors. These cancer specific antigens (TACAs) suppress immune function, provide resistance to chemotherapy, and enable tissue invasion and metastasis. Siamab's platform enables the rapid creation of multiple antibodies to these challenging targets.